In Vitro Activity of Ceftazidime-Avibactam against Contemporary Pseudomonas aeruginosa Isolates from U.S. Medical Centers by Census Region, 2014 | Zendy

Michael D. Huband | Zendy; Mariana Castanheira | Zendy; Robert K. Flamm | Zendy; David J. Farrell | Zendy; Ronald N. Jones | Zendy; Hélio S. Sader | Zendy

Open Access

In Vitro Activity of Ceftazidime-Avibactam against Contemporary Pseudomonas aeruginosa Isolates from U.S. Medical Centers by Census Region, 2014

Author(s) -

Michael D. Huband,

Mariana Castanheira,

Robert K. Flamm,

David J. Farrell,

Ronald N. Jones,

Hélio S. Sader

Publication year - 2016

Publication title -

antimicrobial agents and chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.07

H-Index - 259

eISSN - 1070-6283

pISSN - 0066-4804

DOI - 10.1128/aac.03056-15

Subject(s) - ceftazidime/avibactam , pseudomonas aeruginosa , ceftazidime , broth microdilution , avibactam , microbiology and biotechnology , piperacillin , meropenem , tazobactam , biology , medicine , antibiotics , minimum inhibitory concentration , bacteria , antibiotic resistance , genetics

Thein vitroantibacterial activities of ceftazidime-avibactam and comparator agents were evaluated using reference broth microdilution methods against 1,743Pseudomonas aeruginosaisolates collected in 2014 from 69 U.S. medical centers, representing each of the nine census regions. Ceftazidime-avibactam demonstrated potent activity againstP. aeruginosa, including many isolates not susceptible to ceftazidime, meropenem, and piperacillin-tazobactam. In each of the nine census regions, ceftazidime-avibactam demonstrated the highest percentage of susceptible isolates.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research